source
- Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decisionVertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…
- Anthropic outlines biopharma strategy ahead of potential record-size IPOAnthropic, the AI startup that recently filed paperwork for what could become the largest initial public offering in business history, used its AI Day event to detail its biopharma ambitions. The…